Ref ID: 19485
Author:
H Badali1*, JF Meis2, A Vaezi1
Author address:
1Invasive Fungi Research Center, Mazandaran University of Medical Sciences, Sari, Iran
2Department of Medical Microbiology and infectious disease, Canisius Wilhelmina Hospital, Nijmegen,
The Netherlands
3Invasive Fungi Research Center, Mazandaran
Full conference title:
6th Advances Against Aspergillosis 2014
Abstract:
Purpose:
Triazole antifungal drugs such as itraconazole, posaconazole and voriconazole are the mainstay
of therapy in the management and prophylaxis of aspergillosis. However, in recent years, triazoleresistant
clinical isolates of Aspergillus fumigatus have emerged in Europe (the Netherlands,
Denmark, Spain, UK, Belgium, Germany and France) and Asia (China, India) resulting in several
cases of therapeutic failure caused by triazole-resistant A. fumigatus. Azole resistance may develop
in patients who are treated with long-term azole therapy or may develop in the environment through
the exposure of the fungus to the azole fungicides used in agriculture.
Methods:
In the present study, we investigated the presence of azole resistance in environmental A. fumigatus
isolates from hospital surroundings in Sari and Tehran.
Results:
The TR34/L98H mutation was the only resistance mechanism. Overall 3.3% of the A. fumigatus
isolates from hospital surroundings in Sari and Tehran had the same TR34/L98H STRAf genotype and
was related to some resistant clinical and environmental TR34/L98H isolates from the Netherlands
and India. It is emphasized that routine resistance surveillance studies focusing on environmental
and clinical samples are warranted to yield the true prevalence of azole resistance in A. fumigatus
in Iran.
Conclusion:
The widespread application of triazole fungicides in the environment in Iran could have contributed
to the emergence of environmental azole-resistant A. fumigatus. Given the emergence of azole
resistance in environmental strains, continued surveillance of resistance in clinical A. fumigatus
strains in Iran is desirable for successful therapy of aspergillosis. Furthermore, the need for enhanced
understanding of the evolution of azole resistance and measures to prevent the emergence of multipleazole-
resistant A. fumigatus strains in countries using fungicides can hardly be over-emphasised.
Key words:
Aspergillus fumigatus, cyp51A, TR34/L98H, azole resistance, Iran, microsatellite typing
Abstract Number: 13
Conference Year: 2014
Link to conference website: http://www.AAA2014.org
New link: NULL
Conference abstracts, posters & presentations
-
Title
Author
Year
Number
Poster
-
v
Teclegiorgis Gebremariam [MS]1, Yiyou Gu [PhD]1, Sondus Alkhazraji [PhD]1, Jousha Quran1, Laura K. Najvar [BS]2, Nathan P. Wiederhold [PharmD]2, Thomas F. Patterson [MD]2, Scott G. Filler [MD]1,3, David A. Angulo (MD)4, Ashraf S. Ibrahim [PhD]1,3*,
2024
91
n/a
-
v
Ruta Petraitiene (US)
2024
90
n/a
-
v
Fabio Palmieri (CH), Junier Pilar
2024
89
n/a
-
v
Evelyne Côté (CA)
2024
88
n/a
-
v
Eliane Vanhoffelen (BE)
2024
87
n/a
-
v
Teclegiorgis Gebremariam, Yiyou Gu, Eman Youssef, Sondus Alkhazraji, Joshua Quran, Nathan P. Wiederhold, Ashraf S. Ibrahim
2024
86
n/a
-
v
Thomas Orasch (DE)
2024
85
n/a
-
v
Julien Alex, Katherine González, Gauri Gangapurwala, Antje Vollrath, Zoltán Cseresnyés, Christine Weber, Justyna A. Czaplewska, Stephanie Hoeppener, Carl-Magnus Svensson, Thomas Orasch, Thorsten Heinekamp, Carlos Guerrero-Sánchez, Marc Thilo Figge, Ulrich S. Schubert, Axel A. Brakhage
2024
84
n/a
-
v
Vasireddy Teja, Bibhuti Saha Hod, Soumendranath Haldar (IN)
2024
83
n/a
-
v
Vasireddy Teja, Bibhuti Saha Hod, Soumendranath Haldar (IN)
2024
82
n/a